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Abstract
Background: Pneumococcal diseases remain a leading cause of vaccine-preventable death worldwide in
children <5 years of age. The seven-valent pneumococcal conjugate vaccine (PCV7) was approved in 2001 in Europe
and was introduced into the national immunization programmes of many European countries from 2006–2008. In
2009, higher-valent PCVs (PCV10 and PCV13) became available, replacing PCV7 from 2009–2011. This article describes
the evolution of vaccine and non-vaccine serotypes causing invasive pneumococcal disease (IPD) following the
introduction of PCVs in Western Europe, based on data from publicly-available medical publications and national
surveillance systems from January 2010 to May 2015.
Discussion: In countries with high vaccine uptake, 5–7 years after PCV7 introduction IPD caused by vaccine serotypes
has almost disappeared in children. Non-PCV7 serotypes have emerged, particularly serotypes 19A, 7 F, 3 and 1. A rapid
and significant reduction of the additional serotypes included in higher-valent vaccines has been observed consistently
following the introduction of these vaccines. A significant and rapid decline of serotypes 19A, 7 F, 1 and 6A in both
vaccine-eligible and older age groups has been observed in countries using PCV13 while serotype 19A and 3 has
increased in countries using PCV10. Serotype 3 has become one of the most prevalent serotypes in adults, with
some reduction only in the UK and France. Serotype diversity increased and varied by age group, the type of
vaccine in use, and the time since the introduction of higher-valent PCVs. Serotypes that are currently more
frequent include 24 F, 22 F, 8 and 15A in countries that use PCV13, and serotypes 19A and 3 in countries that
use PCV10. Compared with the time before the introduction of higher valent PCVs, to date, there is no single
‘19A-like’ serotype emerging across countries and most of the newly emerging non-PCV13 vaccine types are less
invasive with a low case-carrier ratio.
Conclusions: It is important to closely monitor not only evolving serotypes but also the magnitude of the effect
in order to evaluate the overall impact of pneumococcal vaccination programmes and to initiate the appropriate
vaccination strategy. Emerging serotypes may also need to be considered for the future development of new
vaccines.
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Background
Pneumococcal diseases remain a leading cause of vaccine-
preventable death worldwide in children <5 years of age
[1]. The first pneumococcal conjugate vaccine (PCV7)
comprising serotypes 4, 6B, 9 V, 14, 18C, 19 F, and
23 F was licensed in 2001 in Europe for the preven-
tion of pneumococcal disease in children. It was in-
troduced into the national immunization programmes
(NIPs) of many European countries between 2006 and
2008. In 2009, higher-valent PCVs became available:
PCV10 (including additional serotypes 1, 5 and 7 F)
and, later PCV13 (including additional serotypes 1, 3,
5, 6A, 7 F and 19A) [2]. These vaccines usually re-
placed PCV7 between 2009 and 2011.
PCV immunization has been successful in decreasing
the mortality and morbidity associated with invasive and
mucosal pneumococcal diseases caused by vaccine sero-
types in children [3–8]. A reduction in nasopharyngeal
carriage of vaccine serotypes has also led to a substantial
herd effect (indirect protection) in the older population
[9]. Following the introduction of PCV7, a marked
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reduction in diseases related to vaccine serotypes has
been observed alongside the emergence of non-vaccine
serotypes [6, 10]. This article describes the evolution of
vaccine and non-vaccine serotypes causing invasive
pneumococcal disease (IPD) following the introduction
of PCVs in Western Europe.
Data are included from national surveillance systems as
well as representative observational studies available
within Medline publications and national surveillance
websites from January 2010 to May 2015 in 15 Western
European countries: Austria, Belgium, Denmark, Finland,
France, Germany, Ireland, Italy, The Netherlands, Norway,
Portugal, Spain, Sweden, Switzerland and the UK. Single-
centred observational studies or clinical trials were not
considered for this review. Only data from original articles
were considered.
Discussion
Countries in which only PCV13 is used
Belgium
PCV7 was introduced into the NIP in January 2007 with a
2 + 1 schedule and was replaced by PCV13 in July 2011.
By 2012, the vaccination coverage was estimated at 98 %
for the first dose and 93 % for the third dose [11].
After 4 years of implementation of PCV7 into the NIP
followed by 2 years of implementation of PCV13, the over-
all incidence of IPD in children <2 years of age decreased
continuously from 155.9 to 56.0/100,000 population
between 2002–2003 and 2013, respectively (Table 1). The
incidence also decreased in those 2–5 years of age but
remained the same in those 5–15 years of age.
In 2010, following the decrease in PCV7-serotype IPD,
non-vaccine-type IPD emerged. At this time, PCV13 se-
rotypes accounted for 73 % of all IPD cases and the most
prevalent serotypes were 19A, 1 and 7 F (60 % of all IPD
cases). In 2013, PCV13 serotypes accounted for 36 % of
IPD cases and serotypes 19A, 1 and 7 F accounted for
29 % of all IPD cases. Serotypes 12 F and 24 F became
more prevalent, representing 12 and 7 % of all IPD
cases, respectively. Serotype 3 was not observed in chil-
dren <5 years of age in 2013 (Table 2) [11]. In 2010,
PCV7 serotypes decreased significantly among indi-
viduals ≥60 years of age, and non-PCV7 serotypes (e.g.,
38, 7, 12 and 22) increased [12].
Denmark
PCV7 was introduced into the NIP with a 2 + 1 schedule
in October 2007. It was replaced by PCV13 in April 2010
with a two-dose catch-up for children 12–17 months of
age. Vaccine coverage for one dose of PCV13 was 92 % in
2011 [13].
In children <2 years of age, the incidence of PCV7-
serotype IPD was significantly reduced from 36.4/100,000
population in 2000–2007 to 3.9/100,000 population in
2008–2010 and to 0.3/100,000 population in 2011–2013,
with only one case caused by 19 F in 2011. The overall
IPD was reduced from 55.1/100,000 population to 16.0/
100,000 population from 2000–2007 to 2011–2013
(Table 1) [14]. In children <3 months of age, PCV7-
serotype disease has not been detected since 2010 [15].
Table 1 Incidence of IPD (/100,000 population) in Western
European countries
Pre-PCV7 period Post-PCV7 period Post-higher
PCV period
Countries in which only PCV13 used
Belgium [11] 2002–2003 2013
<2 years 155.9 56.0
Denmark [14] 2000–2007 2008–2010 2011–2013
<2 years 55.1 25.9 16.0
≥65 years 65.5 60.0 49.4
France [20] 2001–2002 2008–2009 2012
<2 years 30.3 24.6 17.2
>64 years 27.7 31.1 26.5
Ireland [21] 2008 2011 2012
All ages 9.5 7.6 7.6
Norway [25] 2005 2010 2012
<2 years 77.0 20.0 8.1
All ages 23.0 15.0 13.0
Spain (Madrid) [27] - 2007–2010 2011–2012
<15 years - 17.1 7.7
Switzerland [29, 30] 2002–2005 2010 2012
<2 years 27.1 20.6 8.1
≥65 years 42.1 35.2 35.7
UK [31] 2008–2010 2013–2014
<2 years - 22.2 12.0
≥65 years - 27.6 20.6
Countries in which only PCV13 used
Finland [39] 2006 2010 2014
<1 year 68.5 50.7 11.2
>64 years 31.1 32.3 32.5
Countries in which both PCV13 and PCV10 used
Germany [42–44] 1997–2001 2010 2012
<2 yearsa 7.7 4.1 3.7
<2 yearsb 12.7 9.4 6.3
Spain (Navarra) [47] 2001–2003 2004–2009 2010–2013
<5 years 87.1 60.7 18.7
≥65 years 33.6 32.5 25.0
Portugal [48] 2008–2009 2011–2012
<1 year - 52.1 25.1
1-2 years - 31.6 16.1
aPneumococcal meningitis: bpneumococcal non-meningitis IPD
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In adults ≥65 years of age, a similar reduction was also
observed for overall IPD and PCV7-serotype IPD. The
incidence of PCV7-serotype IPD significantly decreased
from 27.1/100,000 population in 2000–2007 to 3.3/
100,000 population in 2011–2013 [14].
In 2008–2010, the most prevalent serotypes were 1,
7 F and 19A in children <5 years of age and 1, 7 F and 3
in those ≥65 years of age [14, 16, 17]. In 2013, serotype
19A significantly increased in all ages following the
introduction of PCV7 but significantly decreased follow-
ing PCV13 introduction (zero cases in children <2 years
of age). Incidence of serotypes 1 and 3 showed no sig-
nificant changes beyond the expected natural cyclical
variations. Non-PCV13 serotypes accounted for nearly
80 % of cases with no clear predominance of a specific
serotype in 2011–2013 [14].
France
PCV7 was introduced into the NIP in June 2006 with 2 + 1
schedule, and was replaced by PCV13 in June 2010 [18].
Vaccine coverage was 94 % in 2009 and remained high in
2012 [19].
Following the introduction of PCV7, the overall
incidence of IPD gradually reduced in children <2 years
of age from 30.3/100,000 population in 2001–2002, to
24.6/100,000 population in 2008–2009 and 17.2/
100,000 population in 2012. In adults >64 years of age,
the incidence increased after the introduction of PCV7
from 27.7 to 31.1/100,000 population (2001–2002 to
2008–2009, respectively), then decreased in 2012 to
26.5/100,000 population, similar to the incidence before
the introduction of PCVs (Table 1).
The incidence of PCV7 serotypes significantly
declined following the introduction of PCV7, and in
2012, PCV7 serotypes accounted for 6 % of all IPD
cases in children <2 years of age and 8 % of cases in
adults ≥50 years of age. In 2009, PCV13 serotypes
accounted for 71 % of all IPD cases in children <2 years
of age, which subsequently declined to 24 % in 2012
(Table 2), mainly due to a significant reduction in
serotypes 19A (83 % reduction), 7 F (77 % reduction), 1
(96 % reduction) and 3 (85 % reduction). The incidence
of non-PCV13 serotypes 24 F and 12 F increased, ac-
counting for 20 and 10 % of all IPD cases, respectively.
In adults >65 years of age, despite a significant de-
crease, PCV13 serotypes remained prevalent (42 % of
all IPD cases) with 19A, 3 and 7 F predominating
(Table 3) [18, 20].
Ireland
PCV7 was introduced into the NIP in September 2008
with a 2 + 1 schedule and was replaced by PCV13 in
December 2010. Vaccine coverage was 91 % in 2012 for
three doses in children < 2 years of age [21].
The overall incidence of IPD in general population
decreased from 9.5/100,00 population in 2008 to 7.6/
100,000 population in 2011 and remained the same in
2012 (Table 1). In 2008, serotype 14 was the most pre-
dominant serotype followed by 4, 9 V, 7 F, 8, 23 F and
6B. These serotypes combined accounted for approxi-
mately 53 % of all IPD cases within the population. In
2010, PCV7-serotype IPD declined by 91 % compared
with 2008 in children <2 years of age and by 50 % in
those >2 years of age. PCV13 serotypes accounted for
Table 2 Prevalence of PCV13 serotypes in Western European countries in children <5 years of age. For details on local vaccine use,
please see text
Age (year) Post-PCV7 period Three most
prevalent
serotypes
Post-higher valent PCV periods Three most
prevalent serotypesYear Among all IPD, % Year Among all IPD, %
Countries in which only PCV13 used
Belgium [11] <5 2010 73 19A, 1, 7 F 2013 36 1, 12 F, 24 F
France [20] <2 2009 71 19A, 7 F, 1 2012 24 24 F, 12 F, 15B/C
Italy [24] <5 2011 64 1, 19A, 22 F 2014 37 19A, 1, 24 F
Norway [25] <5 2010 61 19A, 1, 7 F 2012 26 1, 15B/C
Switzerland [29] <2 2010–2011 68 3, 19A, 7 F 2012 53 3, 23 (not 23 F), 19 F
UK [31] <5 2008–2010 68 7 F, 19A, 1 2013–2014 15 24 F, 22 F, 33 F
Countries in which only PCV10 used
Austria [33, 37] <5 2009 73 3, 14, 18C 2013 93 19A, 7 F, 23 F
Finland [39] <5 2010 92 14, 6B, 19 F 2014 70 19A, 3, 7 F, 23A
Countries in which both PCV13 and PCV10 used
Germanya [44] <16 2008–2009 56 7 F, 1, 18Cb 2012–2013 12 7 F, 10A, 19Ac
Sweden [45] <2 2009 84 22 F, 7 F, 3, 19A 2012 47 33 F, 11
aPneumococcal meningitis; b2007–2010; c2010–2013
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55 % of all IPD cases in all ages at the time PCV13
was introduced. In 2014, the predominant serotypes
were 7 F, 15A, 22 F in all ages [21, 22].
Italy
PCV7 was introduced into immunization programme in
May 2005 as a 2 + 1 schedule and it was replaced by
PCV13 in the summer of 2010. Vaccine coverage differed
between regions and was 50–60 % between 2005 and 2007
[23]. The number of IPD cases reported to the national
laboratory surveillance centre was generally low but did
decrease. In 2005, PCV7 serotypes accounted for 50 % of
all IPD cases in children 0–4 years of age, declining to
31 % of cases in 2007 and 19 % of cases in 2011 (one case
each for 23 and 19 F). In 2011, PCV13 serotypes
accounted for 64 % of all IPD cases, which declined to
37 % in 2014 (Table 2). Between 2007 and 2009, two-
thirds of pneumococcal bacteraemia cases in children were
due to non-PCV7 serotypes; serotype 1 was the most
frequent and was associated with complications, followed
by serotype 19A, which was associated with younger age.
Serotypes 19A and 1 were the most prevalent in 2011 and
remained high in 2014 [24].
Norway
PCV7 was included into the NIP with a 2 + 1 schedule in
July 2006, with a catch-up campaign for children born in
2006 only, and was replaced by PCV13 in April 2011. Vac-
cine coverage was 92 % for children born from 2009 on-
wards [25].
The incidence of overall IPD decreased gradually from
23/100,000 population in 2005 to 15/100,000 population
in 2010 and 13/100,000 population in 2012, one year
after PCV13 introduction (Table 1). The largest decrease
was observed for PCV7-serotype IPD, particularly in
children <2 years of age (incidence of 64/100,000
population in 2005 and zero in 2012). A similar
decrease in other age groups (2–4 years, 50–64 years
and ≥65 years) was also observed [25].
In 2005, PCV7 serotypes accounted for about 63 % of
all IPD cases in children <5 years of age. In 2010, with the
virtual elimination of all PCV7 serotypes (one case of 19 F
reported), PCV13 serotypes comprised 61 % of IPD cases;
serotypes 19A, 1 and 7 F were the most prevalent. In
2012, PCV13 serotypes still accounted for 26 % of all IPD
cases although no cases of PCV13-serotype IPD were
observed in children <2 years of age (Table 2). In
those >5 years of age, PCV7 serotypes comprised 53 % of
IPD cases in 2005, which gradually declined to 8 % in
2012. PCV13 serotypes accounted for 52 % of all IPD
cases in 2010, decreasing to 45 % in 2012 (Table 3). Since
2010, IPD due to serotypes 23B and 15A increased. The
number of cases caused by serotype 1 fluctuated between
1994 and 2002, became stable and then declined in all
ages after the introduction of PCV13. In adults ≥65 years
of age, a decrease in all PCV13 serotypes was observed
with the exception of serotype 3 [25].
Spain (Madrid region)
PCV7 became available in 2001 and was incorporated into
the regional immunization programme in Madrid in
November 2006 with a 2 + 1 schedule and PCV13 was
replaced in June 2010. Vaccine coverage was >90 % in the
Madrid region [26].
In children <15 years of age, the incidence of IPD was
significantly reduced from 17.1/100,000 population in
2007–2010 to 7.7/100,000 population in 2011–2012
(Table 1). In 2007–2009, non-PCV7 serotypes, such as 1,
19A, 5, 7 F and 3, became more prevalent. A significant
reduction of PCV13 serotypes 1 and 19A was observed
following PCV13 introduction in 2010 [27]. No cases of
serotype 19A were observed in children <5 years of age in
Table 3 Prevalence of PCV13 serotypes in Western European countries in older populations
Age (year) Post-PCV7 period Three most
prevalent
serotypes
Post-higher valent PCV periods Three most
prevalent
serotypes
Year Among all IPD, % Year Among all IPD, %
Countries in which only PCV13 used
France [18, 20] ≥65 2009 61 19A, 7 F, 3a 2012 42 19A, 3, 7 Fa
Norway [25] >5 2010 52 7 F, 19A, 1, 3 2012 45 7 F, 19A, 3
Switzerland [29] >64 2010–11 66 3, 19A, 7 F 2012 62 3, 19A, 7 F
UK [31] ≥65 2008–10 54 19A, 3, 22 F 2013–14 21 8, 22 F, 3
Countries in which only PCV10 used
Austria [33, 37] >50 2009 69 3, 6A, 14 2013 59 3, 14, 19A
Finland [39] >65 2010 72 14, 3, 23 F 2014 60 3, 22 F, 19A
Netherlands [41] All ages 2010 60 7 F, 8, 19A, 1 2013 45 8, 7 F, 19A
Countries in which both PCV13 and PCV10 used
Germanya [42, 44] >16 2008–2009 56 3, 7 F, 22 Fb 2012–2013 25 23B, 3, 7 Fc
aPneumococcal meningitis; b2007–2010; c2010–2013
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2013. No significant change in the number of serotype 3
cases was observed, but there was an increase in serotype
8 cases. In 2013, serotypes 8, 3 and 19A were the most
prevalent in the general population [26–28].
Switzerland
PCV7 was introduced into the NIP in November 2005
with a 2 + 1 schedule and was replaced by PCV13 in 2011.
Vaccine coverage was around 76 % in 2012 with ≥2 doses
in children <2 years of age [29].
From 2002–2005 to 2012, the overall IPD incidence
decreased from 12.6 to 10.9/100,000 population. The most
important decrease was in children <2 years of age, from
27.1 to 8.1/100,000 population. In adults >64 years of age,
the decrease in IPD incidence was moderate and remained
relatively high (42.1/100,000 population in 2002–2005 and
35.7/100,000 population in 2012) (Table 1) [29, 30]. In
children <2 years of age, PCV7 serotypes accounted for
66 % of all IPD cases in 2004, which reduced to 17 % in
2010–2011 with the emergence of non-PCV7 serotypes,
such as 3, 19A and 7 F. PCV13 serotypes comprised
68 % of IPD cases in 2010–2011, declining to 53 % in
2012, one year after PCV13 introduction. Serotypes 3
and 23 (not 23 F) remained the most prevalent serotypes
in children, followed by 19 F (Table 2). In adults >64 years
of age, PCV13 serotypes accounted for 66 % of all IPD
cases in 2010–2011 and 62 % of cases in 2012. Serotypes
3, 19A and 7 F were the most prevalent in 2010–2012
(Table 3) [29, 30].
United Kingdom
PCV7 was introduced into the NIP in September
2006 with a 2 + 1 schedule and was replaced by
PCV13 in April 2010. Vaccine coverage was >90 %
in 2012–2013 [31].
The overall incidence of IPD significantly declined in
all ages following PCV7 introduction in 2006 and
PCV13 in 2010. From 2008–2010 to 2013–2014, the
IPD incidence decreased from 22.2 to 12/100,000 popu-
lation in children <2 years of age and from 27.6 to 20.6/
100,000 population in adults >64 years of age (Table 1).
In 2008–2010, non-PCV7 serotypes became prevalent, not-
ably 7 F, 19A and 1 in children <5 years of age and 19A, 3
and 22 F in adults ≥65 years of age (Tables 1 and 2). The
incidence of PCV7-serotype IPD reached near-extinction
in 2013–2014 (0.20/100,000 population). Serotypes 6A/6C
also significantly decreased in children <5 years of age.
Four years after the introduction of PCV13, the
proportion of PCV13 serotypes decreased from 68 %
(2008–2010) to 15 % (2013–2014) in children <5 years
of age and from 54 % (2008–2010) to 21 % (2013–2014)
in adults ≥65 years of age (Table 2). Serotypes 19A, 1,
7 F, 3 and 6A were significantly reduced, although year-
on-year fluctuations were observed for serotype 3.
Serotype 3 significantly decreased (44 % reduction) but
remained prevalent in adults ≥65 years of age. Serotype
5, which is an outbreak strain, has not been detected
in recent years. Non-vaccine serotypes generally in-
creased in all ages and significantly in those >50 years
of age. The most common serotypes were 24 F, 22 F
and 33 F in children <5 years of age and 8, 22 F and 3
in adults ≥65 years of age (Tables 2 and 3) [10, 31].
Countries in which only PCV10 is used
Austria
In 2012, PCV10 was the first PCV introduced into NIP
with a 2 + 1 schedule. Vaccine coverage in 2012 was over
90 % [32].
Annually, about 200 to 330 IPD cases were reported
to the national reference centre between 2009 and 2013
[33–37]. From 2011 to 2013, the total reported number
of IPD cases in children <5 years of age was stable, with
14 reported cases per year (compared with 22 cases each
in 2009 and 2010). PCV10 and PCV13 serotypes com-
prised 41 and 73 %, respectively, of all IPD cases in 2009
and 71 and 93 %, respectively, of IPD cases in 2013
(Table 2). In adults >50 years of age, PCV10 and PCV13
serotypes accounted for 37 and 69 %, respectively, of all
IPD cases in 2009 and 25 and 59 %, respectively, of IPD
cases in 2013 (Table 3). From 2009, serotype 3 was the
most prevalent serotype for IPD in all ages, fluctuating
from 16 to 22 % of all cases. Other common serotypes
were 14, 19A and 7 F. In 2013, 88 % of IPD cases caused
by serotype 3 occurred in individuals >50 years of age
while only one case was reported in children <5 years of
age. Serotype 14 accounted for 7–11 % of all IPD cases
between 2009 and 2013. Serotype 19A comprised 3 % of
all IPD cases in 2009, increasing to 6–7 % in 2010–2013.
Finland
PCV10 was the first PCV in Finland, introduced in
September 2010 with a 2 + 1 schedule. Vaccine coverage
was estimated as 95 % in 2012–2013 [38].
From 2004 to 2010, the incidence of IPD in chil-
dren <1 year of age ranged from 50 to 69/100,000
population and from 27 to 37/100,000 population in
those >64 years of age. In children <1 year of age, the in-
cidence/100,000 population gradually decreased after the
introduction of PCV10 to 50.7 in 2010 and 11.2 in
2014. From 2010 to 2014, the overall IPD incidence
in adults >64 years of age remained unchanged at
30–33/100,000 population due to an increase in non-
PCV10-serotype IPD despite a significant reduction in
PCV10-serotype IPD in all ages (Table 1) [39].
In children <5 years of age, PCV10 and PCV13 serotypes
accounted for 84 and 92 %, respectively, of all IPD isolates
in 2010. By 2014, PCV10 serotypes decreased significantly
and accounted for 19 % of all IPD isolates reported.
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However, although the number of isolates was small,
the three additional serotypes included in PCV13 in-
creased, representing 51 % all isolates. The most preva-
lent serotypes in 2014 were 19A (30 %), and 3 (19 %)
(Table 2). In adults >65 years of age, PCV10 and PCV13
serotypes accounted for 55 and 72 %, respectively, of all
IPD isolates in 2010. By 2014, PCV10 serotypes had
significantly decreased and accounted for 26 % of all iso-
lates while the three additional serotypes included in
PCV13 increased, comprising 34 % of all isolates (Table 3).
The most prevalent serotypes in 2010 were 14 (15 %), 3
(10 %), 23 F (8 %); in 2014 these were 3 (17 %), 22 F
(12 %) and 19A (11 %). Serotypes 3 and 19A have in-
creased gradually over the last 5 years (2010–2014) with
significant numbers of cases occurring in older age groups
(>50 years of age) [39].
The Netherlands
PCV7 was introduced into the NIP in June 2006 with a
3 + 1 schedule and it was replaced by PCV10 in April
2011. In November 2013, vaccine schedule was reduced
to 2 + 1 [40]. Vaccine coverage was high with ≥94 % of
infants born between April 2006 and 2008 receiving full
vaccination by the age of 2 years [41].
Introduction of PCV7 into NIP in 2006 led to a major
decrease in IPD due to PCV7 serotypes vaccine-type from
7.4 per 100,000 per year in 2004–2006 to less than 1 per
100,000 per year in 2012–2014 [40]. According to data
from nine sentinel laboratories, in 2006, PCV7 serotypes
accounted for 48 % of all reported blood isolates, which
reduced substantially to 17 % in 2010 and further decreased
to 7 % in 2013. In 2010, PCV10 and PCV13 serotypes
accounted for 42 and 60 % of all IPD isolates, and the most
prevalent serotypes were 7 F, 8, 19A and 1, comprising
46 % of all IPD isolates (Table 3). Two years after PCV10
was introduced into the NIP, these serotypes remained the
most prevalent: of all isolates, 17 % were serotype 8, 12 %
were serotype 7 F, 10 % were serotype 19A and 8 % were
serotype 3. The proportion of PCV10-serotype IPD iso-
lates reduced to 28 % and the proportion of IPD isolates
containing the three additional serotypes included in
PCV13 remained the same (17 %). Since 2009, serotypes
8, 12 F, 19A, 3, 22 F have gradually increased. No substan-
tial change in prevalence was observed for serotypes 7 F
and 5 [41].
Countries in which both, PCV13 and PCV10 are used
Germany
PCV7 was introduced in July 2006 as part of the NIP with
a 3 + 1 schedule and was replaced by higher-valent vaccines
(PCV10 and PCV13) in 2009. Vaccine coverage was esti-
mated at about 98 % for the first dose but only 64 % for the
booster dose in 2014 and PCV 13 was predominantly used
with >90 % market share [42].
The overall incidence of pneumococcal meningitis
decreased significantly in children <16 years of age
from 1.5 to 0.9/100,000 population between 1997-2001
and 2010, respectively, with a further reduction to 0.7/
100,000 population in 2012. This was driven by the
reduction in the incidence of pneumococcal meningitis
in children <2 years of age, from 7.7 (1997–2001) to 4.1
(2010) and 3.7/100,000 population (2012). A substantial
reduction was observed in non-meningitis IPD, most
importantly in children <2 years of age (Table 1) [42, 43].
In children <16 years of age among pneumococcal men-
ingitis, PCV7 serotypes accounted for 65 % in 2005–2006
and reduced to zero in 2012–2013. PCV13 serotypes
accounted for 83 % in 2005–2006, 56 % in 2008–2009 and
reduced to 12 % in 2012–2013. Similar trend was observed
in adults >16 years of age for PCV13 serotypes IPD: 68 %
in 2005–2006, 56 % in 2009–2010 and 25 % in 2012–2013
(Tables 2 and 3) [44].
In children <16 years of age, the most prevalent serotypes
were 14 and 18C in pre-PCV7 period, 7 F, 18C and 1 in
post-PCV7 period and 7 F, 19A and 10A in 2010–2013. In
the adult population (>16 years of age), the most prevalent
serotypes during 1992–2006 were 23B and 14. During
2007–2009, serotypes 3 and 7 F accounted for 13 and 7 %,
respectively, of all IPD cases, and in 2010–2013, after the
introduction of higher-valent PCVs, serotypes 7 F, 23B and
3 accounted for 27 % of all IPD cases (Table 3). PCV13-
serotype IPD significantly reduced while a diversity of non-
PCV13 serotypes emerged in some age groups. Compared
with the period following the introduction of PCV7, sero-
type 3 increased in children, albeit in very small numbers,
and decreased in adults >16 years of age. A significant
increase in serotype 23B was observed for all ages [42, 44].
Sweden
PCV7 was introduced in January 2009 as part of the NIP
with a 2 + 1 schedule and was replaced by higher-valent
vaccines (PCV10 and PCV13) in 2010. Both higher-valent
PCVs are currently used in the immunization pro-
grammes of different Swedish counties. PCV coverage in
children <2 years of age was 98 % in 2012 and 2013 [45].
The overall IPD incidence ranged from 14.4 to 19.5/
100,000 population during 2005–2011. Compared with
the average IPD incidence in 2005–2007, incidence in
2012 decreased by 75 % and 57 % in children aged <2 years
and 2–4 years of age, respectively. Among adults, no
major changes were observed. In 2008, PCV7 serotypes
accounted for 68 % of all IPD cases in children <2 years of
age and this gradually decreased to 12 % in 2012. In
2009 (before the introduction of higher-valent PCVs),
PCV13 serotypes accounted for 84 % of all IPD cases in
children <2 years, which reduced to 47 % in 2012
(Table 2). In addition, there was a reduction in the pro-
portion of IPD caused by PCV13 in all age groups
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(74 % in 2009 to 48 % in 2012). Serotypes 22 F, 7 F, 3 and
19A were the most common serotypes in 2011 and 2012.
Serotypes 33 F and 11 became important in 2012 [45].
Spain (Catalonia, Navarra)
In Catalonia and Navarra, PCV7 became available in 2001
in the private market with a 3 + 1 schedule. PCV13 and
PCV10 became available in 2010. Vaccine uptake was
around 50 % in Catalonia and 78 % in Navarra in 2013.
PCV13 was the most commonly used vaccine [46, 47].
In Catalonia, PCV7 serotypes accounted for 21 % of
IPD cases in 2005, which reduced to 13 % in 2009. 19A
was the most prevalent serotype followed by 14 and 1 in
children <2 years of age. Serotype 1 was the most preva-
lent serotype followed by 19A in children 2–4 years of
age. During 2005–2009, the most common serotypes in
adults >65 years of age were 1, 3, 19A and 14 [46].
During 2001–2003 in Navarra, the overall incidence of
IPD was highest with 87.1/100,000 population in chil-
dren <5 years and 33.6 in adults ≥65 years of age. It was
significantly reduced to 18.7/100,000 in children <5 years
of age and 25.0/100,000 in adults ≥65 years of age in
2010–2013. The reduction was driven by PCV7 and
PCV13 serotypes, particularly in children <5 years of
age. The incidence of PCV7-serotype IPD decreased
from 42.9 to 0.7/100,000 population and that of add-
itional PCV13-serotype IPD from 37.7 to 8.6/100,000
population from 2001–2003 to 2010–2013 (Table 1).
During 2004–2009, PCV7- and PCV13-serotypes ac-
counted for 9 and 78 % respectively, of all IPD cases in
children <5 years of age and 19 and 72 %, respectively,
of cases in those ≥5 years of age. The most predominant
serotype was 19A, which reduced from 32 to 24 % following
the use of PCV13 in children <5 years of age. The decrease
was less prominent in those ≥5 years of age, from 14 %
(PCV7 serotypes) to 11 % (PCV13 serotypes). Serotypes
19A, 3 and 7 F remained important from 2010–2013 [47].
Portugal
PCV7 became available in Portugal in 2001 in the private
market with 3 + 1 schedule. Vaccine coverage was 75 % in
2008. In 2009 and 2010 PCV10 and PCV13, respectively,
were made available and by 2010, PCV13 was the most
commonly used vaccine [48, 49].
A decline in the overall proportion of PCV7-serotype
IPD cases in children since 2002 has been observed. PCV7
serotypes accounted for 56 % of infections in 1999–2002
and decreased to 17 % in 2006–2008 [49]. Following the
use of higher-valent PCVs in 2010, the incidence of overall
IPD decreased in children, particularly in young children,
from 52.1 (2008–2009) to 25.1/100,000 population
(2011–2012) in children <1 year of age and from 31.6
(2008–2009) to 16.1/100,000 population (2011–2012)
in children 1–2 years of age. These decreases were
driven by reductions in PCV13-serotype IPD, from 43.6
(2008–2009) to 14.8/100,000 population (2011–2012)
in children <1 year of age and from 28.0 to 9.1/100,000
population in children 1–2 years of age (Table 1) [48].
During 2006–2008, the most common isolates in
children were 1 (24 %), 19A (20 %), 7 F (12 %), 14 (7 %)
and 3 (6 %). Serotype 1 was associated with cases of
empyema and occurred more often in older children and
19A occurred in younger children (<2 years of age) [49].
In 2008–2009, the most prevalent serotypes in children
under 18 years of age remained the same: 1 and 19A
followed by 7 F and 14, which decreased substantially in
2011–2012. Non-vaccine serotypes, notably 10A, increased
in children.
In the adult population in 2008, PCV7-serotype IPD
significantly decreased, accompanied by a significant
increase in serotypes 1, 7 F and 19A. PCV13 serotypes
accounted for 70 % of all IPD cases in 2008 and decreased
to 54 % in 2011 which was mainly driven by decrease in
prevalence of serotype 1 and 5. In 2009–2011, the most
predominant serotypes were 3 (13 % of all isolates)
followed by 7 F, 19A, 14, 1 and 8 [50].
Conclusion
The epidemiology of pneumococcal diseases has sig-
nificantly changed with the implementation of routine
childhood pneumococcal vaccination programmes in
Western Europe. The overall incidence of IPD has
decreased (Table 1), mainly driven by significant decreases
of vaccine-type IPD in individuals of vaccine-eligible age
as well as decreases in older individuals not eligible for
pneumococcal vaccination in countries with high vaccine
coverage. After 7–10 years of PCV7 use, the incidence of
PCV7-serotype IPD became very low in all ages with vir-
tual elimination in children, particularly in countries with
high vaccine coverage, such as Belgium, Denmark, France,
Norway and the UK [4, 5, 11, 14, 20, 25, 31]. Non-PCV7
serotypes became more frequent, particularly 19A, 7 F, 3
and 1 some years after the introduction of PCV7 [4, 5].
With the introduction of higher-valent vaccines, a rapid
and significant reduction of additional serotypes included
in these vaccines was consistently observed. In countries
that used PCV13, the proportion of PCV13-preventable
IPD cases in children <5 years of age declined significantly
from 61–73 % in the period after the introduction of
PCV7 to 15–53 % in the period after the introduction of
PCV13 (Table 2). This was mainly driven by a significant
and rapid decline of serotypes 19A, 7 F, 1 and 6A in both
vaccine-eligible ages and older age groups (indirect effect).
However, despite significant direct and indirect protection,
vaccine serotypes such as 19A, 7 F and 3 were still circu-
lating and prevalent in children. These serotypes were par-
ticularly important in older age groups. The extent of
reduction of vaccine serotypes in older population (indirect
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effect) was lesser in the early period after the introduction
of PCV13 compared with later periods and in countries
with lower paediatric vaccine uptake. After 1–2 years after
introduction in France, Norway and Switzerland, PCV13
serotypes accounted for 42–62 % of all IPD while only
21 % in the UK at 4 years after PCV13 introduction
(Table 3).
In countries that used PCV10, the proportion of
PCV13-preventable IPD cases remained high (70–86 % in
vaccine-eligible ages), with a predominance of serotype
19A and 3 (Table 2). While some post-marketing case
control and cohort-based studies have suggested potential
cross-protection of PCV10 against 19A IPD in young
children [38, 51, 52], a decrease in IPD caused by serotype
19A in older children and in adult populations was not
observed. In fact, serotype 19A became significantly and
increasingly prevalent, particularly in older age groups in
Finland, the Netherlands and Austria (Table 3). A similar
trend was observed in New Zealand [53]. In children, the
incidence of serotype 3 was very low and reported
numbers remained unchanged in most countries. A
case–control study in the UK suggested that the
effectiveness of PCV13 for serotype 3 in all age groups
was non-significant [54]. However, a case–control study in
the US (3 + 1 schedule) had described a significant vaccine
effectiveness of 76 % (95 % CI 13; 93) against serotype 3
[55] and relevant decreases in serotype 3 IPD were
observed in larger observational studies in the UK and
France [20, 31].
Serotype diversity generally increased, with diverse se-
rotypes emerging depending on the country, time from
introduction of higher-valent PCVs and the types of
vaccine used. However, newly emerging non-PCV13
vaccine types were shown to be less invasive with low
case-carrier ratio [56, 57] and no individual serotype has
emerged in the same way as serotypes 19A and 7 F
emerged after the introduction of PCV7. To date,
serotypes 24 F, 22 F, 8 and 15A are becoming important
in countries that use PCV13 and serotypes 19A and 3 in
countries that use PCV10. In this review, otitis media
and pneumococcal pneumonia and related serotypes
were not discussed, despite the fact that the public
health value of pneumococcal vaccination is largely
based on the these diseases. However, given the diagnostic
and ethical problems to obtain appropriate cultures for
testing, the serotype epidemiology of non-invasive diseases
is largely unknown. In this respect, nasopharyngeal car-
riage studies may serve as a surrogate to monitor the sero-
type evolution in non-invasive diseases, as mucosal
pneumococcal diseases results from direct infection.
The knowledge of emerging vaccine serotypes is
important to continuously monitor the risk-benefit pro-
file of PCVs. The data presented here are also needed to
develop next generation pneumococcal vaccines.
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